Literature DB >> 24937308

Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design.

Vijaya Madhavi1, Leia H Wren, Rob J Center, Christopher Gonelli, Wendy R Winnall, Matthew S Parsons, Marit Kramski, Stephen J Kent, Ivan Stratov.   

Abstract

OBJECTIVE: The objective of this study is to determine the breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity (ADCC) in HIV controllers and HIV progressors with a view to design globally relevant HIV vaccines.
DESIGN: The breadth of ADCC towards four major HIV-1 Env subtypes was measured in vitro for 11 HIV controllers and 11 HIV progressors.
METHODS: Plasma from 11 HIV controllers (including long-term slow progressors, viremic controllers, elite controller and posttreatment controller) and 11 HIV progressors, mostly infected with HIV-1 subtype B, was analysed for ADCC responses. ADCC assays were performed against 10 HIV-1 gp120 and 8 gp140 proteins from four major HIV-1 subtypes (A, B, C and E) and 3 glycosylation-mutant gp140 proteins.
RESULTS: ADCC-mediated natural killer cell activation was significantly broader (P = 0.02) and of higher magnitude (P < 0.001) in HIV controllers than in HIV progressors. HIV controllers also showed significantly higher magnitude of ADCC-mediated killing of Env-coated target cells than HIV progressors to both HIV-1 subtype B and the heterologous subtype E gp140 (P = 0.001). We found good ADCC reactivity to subtype B and E Envs, less cross-reactivity to subtype A and minimal cross-reactivity to subtype C Envs. Glycosylation-dependent ADCC epitopes comprise a significant proportion of the total Env-specific ADCC response, as evident from the reduction in ADCC to nonglycosylated form of HIV-1 gp140 (P = 0.004).
CONCLUSION: HIV controllers have robust ADCC responses that recognize a broad range of HIV-1 Env. Glycosylation of Env was found to be important for recognition of ADCC epitopes. Identifying conserved ADCC epitopes will assist in designing globally relevant ADCC-based HIV vaccines.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24937308     DOI: 10.1097/QAD.0000000000000310

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  22 in total

1.  HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV.

Authors:  Vijaya Madhavi; Bruce D Wines; Janaki Amin; Sean Emery; Ester Lopez; Anthony Kelleher; Rob J Center; P Mark Hogarth; Amy W Chung; Stephen J Kent; Ivan Stratov
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

Review 2.  Antibody-dependent cellular cytotoxicity in HIV infection.

Authors:  Donald N Forthal; Andrés Finzi
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

3.  Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors.

Authors:  Saheli Sadanand; Jishnu Das; Amy W Chung; Matthew K Schoen; Sophie Lane; Todd J Suscovich; Hendrik Streeck; Davey M Smith; Susan J Little; Douglas A Lauffenburger; Douglas D Richman; Galit Alter
Journal:  AIDS       Date:  2018-02-20       Impact factor: 4.177

4.  Neutralizing Antibody Response and Antibody-Dependent Cellular Cytotoxicity in HIV-1-Infected Individuals from Guinea-Bissau and Denmark.

Authors:  Marie Borggren; Sanne Skov Jensen; Leo Heyndrickx; Angelica A Palm; Jan Gerstoft; Gitte Kronborg; Bo Langhoff Hønge; Sanne Jespersen; Zacarias José da Silva; Ingrid Karlsson; Anders Fomsgaard
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-07       Impact factor: 2.205

5.  Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period.

Authors:  Paul Spearman; Georgia D Tomaras; David C Montefiori; Ying Huang; Marnie L Elizaga; Guido Ferrari; S Munir Alam; Abby Isaacs; Hasan Ahmed; John Hural; M Juliana McElrath; Laissa Ouedraogo; Michael Pensiero; Chris Butler; Spyros A Kalams; Edgar Turner Overton; Susan W Barnett
Journal:  J Infect Dis       Date:  2019-05-05       Impact factor: 5.226

6.  Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG.

Authors:  Raymond A Alvarez; Ana M Maestre; Kenneth Law; Natasha D Durham; Maria Ines Barria; Akiko Ishii-Watabe; Minoru Tada; Manav Kapoor; Mathew T Hotta; Gabriela Rodriguez-Caprio; Daniel S Fierer; Ana Fernandez-Sesma; Viviana Simon; Benjamin K Chen
Journal:  JCI Insight       Date:  2017-02-23

Review 7.  Engaging innate immunity in HIV-1 cure strategies.

Authors:  Nathan L Board; Milica Moskovljevic; Fengting Wu; Robert F Siliciano; Janet D Siliciano
Journal:  Nat Rev Immunol       Date:  2021-11-25       Impact factor: 108.555

Review 8.  Antibodies for Human Immunodeficiency Virus-1 Cure Strategies.

Authors:  Evan Rossignol; Galit Alter; Boris Julg
Journal:  J Infect Dis       Date:  2021-02-15       Impact factor: 5.226

9.  Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells.

Authors:  Evan D Rossignol; Anne-Sophie Dugast; Hacheming Compere; Christopher A Cottrell; Jeffrey Copps; Shu Lin; Deniz Cizmeci; Michael S Seaman; Margaret E Ackerman; Andrew B Ward; Galit Alter; Boris Julg
Journal:  Cell Rep       Date:  2021-05-25       Impact factor: 9.423

10.  HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.

Authors:  Katherine L Williams; Valerie Cortez; Adam S Dingens; Johannes S Gach; Stephanie Rainwater; Julie F Weis; Xuemin Chen; Paul Spearman; Donald N Forthal; Julie Overbaugh
Journal:  EBioMedicine       Date:  2015-10       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.